Lilly-Boehringer's diabetes treatment does well in late-stage study

08/18/2013 | Genetic Engineering & Biotechnology News

Elderly patients with type 2 diabetes who received Boehringer Ingelheim and Eli Lilly and Co.'s dipeptidyl peptidase-4 inhibitor linagliptin for 24 weeks showed significant reductions in blood glucose levels compared with those treated with a placebo, a late-stage trial found. The safety and tolerability profile was comparable to that of the placebo.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD